This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van de Werf, F. Articles by Collen, D. Search for Related Content PubMed PubMed Citation Articles by Van de Werf, F. Articles by Collen, D. Pubmed/NCBI databases Substance via MeSH

Circulation, Vol 69, 605-610, Copyright © 1984 by American Heart Association

ARTICLES

Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology

F Van de Werf, SR Bergmann, KA Fox, H de Geest, CF Hoyng, BE Sobel and D Collen

Coronary thrombolysis was induced by intravenous infusion of human tissue-type plasminogen activator (recombinant human t-PA or rt-PA) obtained by expression of the cloned gene in a mammalian cell system. Thrombolysis was detected by the appearance of reperfusion arrhythmia and confirmed by repeat angiography in anesthetized dogs with 1-hr-old thrombi of the left anterior descending coronary artery that were induced with a copper coil. Infusion of 1000 IU (10 micrograms)/kg/min intravenous rt-PA (n = 9) elicited reperfusion within 13.7 +/- 1.9 min (mean +/- SE) without producing systemic fibrinolysis or distal coronary embolization. Infusion of urokinase at the same rate elicited thrombolysis in seven of 10 dogs within an average of 19.3 +/- 2.2 min. However, distal coronary embolization occurred in two dogs and systemic fibrinolysis was observed in all. In three dogs treated with urokinase thrombolysis was obtained only with subsequent intracoronary infusion. Restoration of myocardial perfusion and metabolism assessed with positron-emission tomography was consistently noted in dogs treated with rt-PA. Thus, rt-PA, a clot-selective thrombolytic agent that does not activate the fibrinolytic system systemically and that is potentially available in large quantities, in view of its synthesis by recombinant DNA technology, offers a promising practical approach for coronary thrombolysis in patients with acute myocardial infarction.

This article has been cited by other articles:

				D. Collen and H.R. Lijnen The Tissue-Type Plasminogen Activator Story Arterioscler Thromb Vasc Biol, August 1, 2009; 29(8): 1151 - 1155. [Abstract] [Full Text] [PDF]

				J.-N. Liu, J.-X. Liu, B.-f. Liu, Z. Sun, J.-L. Zuo, P.-x. Zhang, J. Zhang, Y.-h. Chen, and V. Gurewich Prourokinase Mutant That Induces Highly Effective Clot Lysis Without Interfering With Hemostasis Circ. Res., April 19, 2002; 90(7): 757 - 763. [Abstract] [Full Text] [PDF]

				E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy Intravenous Thrombolysis in Acute Myocardial Infarction Chest, January 1, 2001; 119 (2009): 253S - 277S. [Full Text] [PDF]

				S. V. Pislaru, Y. Ni, C. Pislaru, H. Bosmans, Y. Miao, J. Bogaert, S. Dymarkowski, W. Semmler, G. Marchal, and F. J. Van de Werf Noninvasive Measurements of Infarct Size After Thrombolysis With a Necrosis-Avid MRI Contrast Agent Circulation, February 9, 1999; 99(5): 690 - 696. [Abstract] [Full Text] [PDF]

				S. Pislaru, C. Pislaru, M. Szilard, J. Arnout, and F. Van de Werf In vivo effects of contrast media on coronary thrombolysis J. Am. Coll. Cardiol., October 1, 1998; 32(4): 1102 - 1108. [Abstract] [Full Text] [PDF]

				T. IKEDA, S. NAKATANI, H. TAKATA, M. NOSAKA, A. YOSHIKAWA, H. TANAKA, and S. YUKAWA Effect of tPA on Regional Lung Perfusion in Unilobar Canine Pulmonary Thromboembolism Am. J. Respir. Crit. Care Med., November 1, 1997; 156(5): 1483 - 1486. [Abstract] [Full Text]

				D. Collen Fibrin-Selective Thrombolytic Therapy for Acute Myocardial Infarction Circulation, March 1, 1996; 93(5): 857 - 865. [Full Text]

				T. Tomaru, Y. Uchida, H. Sonoki, M. Tsukamoto, and T. Sugimoto The Thrombolytic Effects of Native Tissue-Type Plasminogen Activator (AK-124) on Experimental Canine Coronary Thrombosis Angiology, May 1, 1989; 40(5): 429 - 435. [Abstract] [PDF]

				R. W. Snyder, F. H. Lambrou, and G. A. Williams Intraocular Fibrinolysis With Recombinant Human Tissue Plasminogen Activator: Experimental Treatment in a Rabbit Model Arch Ophthalmol, September 1, 1987; 105(9): 1277 - 1280. [Abstract] [PDF]

				G. R. Curl, J. A. Jakubowski, D. C. Nabseth, and H. L. Bush Jr Efficacy of Tissue Plasminogen Activator and Urokinase in a Canine Model of Prosthetic Graft Thrombosis Arch Surg, July 1, 1986; 121(7): 782 - 788. [Abstract] [PDF]

				D.C. Stump, H.R. Lijnen, and D. Collen Biochemical and Biological Properties of Single-chain Urokinase-type Plasminogen Activator Cold Spring Harb Symp Quant Biol, January 1, 1986; 51(0): 563 - 569. [Abstract] [PDF]

				Thrombolysis for Evolving Myocardial Infarction Ann Intern Med, September 1, 1985; 103(3): 463 - 469. [Abstract] [PDF]

				J.-N. Liu, J.-X. Liu, B.-f. Liu, Z. Sun, J.-L. Zuo, P.-x. Zhang, J. Zhang, Y.-h. Chen, and V. Gurewich Prourokinase Mutant That Induces Highly Effective Clot Lysis Without Interfering With Hemostasis Circ. Res., April 19, 2002; 90(7): 757 - 763. [Abstract] [Full Text] [PDF]